oesophageal squamous cell carcinoma
Oncology · 2021–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tislelizumab First-line treatment of patients with unresectable, locally advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (OSCC), in combination with… | Nov 2024 | Recommended with restriction | input received Rare Cancers Australia · Pancare Foundation · Medical Oncology Group |
| nivolumab Advanced or metastatic oesophageal squamous cell carcinoma (OSCC), agnostic to PD-L1 status, in first-line and second-line settings, as well as first-line… | Jul 2023 | Recommended with restriction | no section in document |
| nivolumab Second-line treatment of advanced or metastatic oesophageal squamous cell carcinoma (OSCC) after fluoropyrimidine and platinum-based chemotherapy. | Mar 2022 | Recommended with restriction | input received Medical Oncology Group |
| nivolumab Advanced or metastatic oesophageal squamous cell carcinoma (OSCC) in patients who have failed one fluoropyrimidine and platinum-based chemotherapy treatment… | Jul 2021 | Recommended with restriction | input received Rare Cancers Australia · Pancare Foundation · Medical Oncology Group |
Who spoke
Medical Oncology Group · Rare Cancers Australia · Pancare Foundation
What the PBS pays
$86M in government benefit over 2024–25, across 7,990 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| nivolumab | $85.2M |
| tislelizumab | $0.3M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| nivolumabNivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma | TA865 | recommended restricted | 2023-02 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.